Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXB-251
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VXB-251 is a trivalent viral vaccine candidate developed by Vicebio for the prevention of respiratory infections caused by respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). It utilizes Vicebio’s proprietary Molecular Clamp technology, which stabilizes viral glycoproteins in their highly immunogenic prefusion conformation to elicit strong protective immune responses. The goal is to provide robust immunity against multiple major respiratory pathogens in a single formulation, addressing significant unmet needs particularly among elderly and immunocompromised populations. As of October 2024, VXB-251 remains in preclinical development[1][2][5][6][7].
- Brand names
- VXB-251VXB251VXB 251
- Other names
- RSV-hMPV-PIV3 vaccineRSV-hMPV-PIV-3 vaccineRSV-hMPV-PIV 3 vaccineTrivalent RSV-hMPV-PIV3 vaccine
Beyond the preview
Go deeper on VXB-251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXB-251.